TB-500 is a synthetic peptide fragment tied to the actin-binding region of thymosin beta-4, and in the United States it sits in an unapproved, largely unregulated-as-a-medicine position. No formulation has FDA approval for human use, so the published record places it outside the lawful pathways for drugs, dietary supplements, and compounded preparations alike, even though it is not a federally scheduled controlled substance.
TB-500 has no FDA approval for human use in the United States, cannot be lawfully marketed or sold to treat any condition, and is not a recognized dietary supplement ingredient, despite not being a federally scheduled controlled substance.
The agency's approved-drug list contains no TB-500 product, and the record shows it studied chiefly in preclinical and animal contexts rather than the pivotal human trials approval requires. An unapproved drug is one the FDA has never cleared for marketing, which differs from an investigational drug being studied under an active IND with agency oversight; the research-chemical supply sits in the former category, outside any sanctioned framework.
No TB-500 product has FDA approval for human use, and the April 15, 2026 removal from Category 2 lifted the explicit prohibition but did not add it to the 503A bulks list, so it remains uncleared for routine compounding.
Research-chemical labeling exists because it lets material be sold for in-vitro and non-clinical work without the substance being approved as a medicine, and TB-500 is commonly distributed this way. The published view is that the "not for human consumption" disclaimer is weak protection: regulators judge a product's actual intended use from the totality of how it is marketed, so a label does not immunize a seller whose overall presentation signals human use.
A "not for human consumption" label does not place a product outside FDA drug rules, because regulators assess intended use from the totality of the marketing, including dosing guidance, testimonials, and accessories, rather than the disclaimer alone.
The published reading of the Dietary Supplement Health and Education Act is that TB-500 does not fit the legal definition of a dietary ingredient. A synthetic peptide fragment intended for injection does not fall within the recognized categories, and the injectable route alone pushes a product toward drug status rather than supplement status.
TB-500 is not a lawful dietary supplement ingredient because a synthetic injectable peptide fragment falls outside DSHEA's recognized categories, and the FDA has treated peptide products marketed as supplements as unapproved or misbranded drugs.
The record is clear that TB-500 is not a scheduled controlled substance, and the published material flags this as a frequent point of confusion. As a thymosin beta-4 fragment it appears on no DEA schedule, which sets it apart from anabolic-androgenic steroids that Congress specifically placed in Schedule III, yet that absence of scheduling does not establish legality for human use.
| Criteria | Anabolic Steroids | TB-500 |
|---|---|---|
| Federal scheduling | Schedule III under the CSA | Not scheduled |
| Enforcing regime | DEA controlled-substance controls | No DEA control applies |
| Non-medical distribution | Criminal penalties | Not a controlled-substance offense |
| FDA approval for human use | Varies by product | None |
TB-500 appears on no DEA schedule and is not a controlled substance the way anabolic steroids in Schedule III are, but being unscheduled means only that the DEA regime does not apply, not that the FDA's drug-approval requirements are met.
The published record shows the FDA repeatedly using its enforcement tools against companies that market injectable peptides for human use, with a toolkit running from warning letters to import alerts, seizures, injunctions, and criminal referrals. The documented pattern is consistent: the agency looks past the label to the real-world marketing, and peptides promoted for human benefit are treated as unapproved drugs.
Therapeutic and structure-function claims sharply raise enforcement exposure by removing any ambiguity about intended use, and documented FDA actions against injectable-peptide sellers range from warning letters to import blocks, seizures, injunctions, financial penalties, and criminal charges.
In regulated competition the answer is unambiguous: the World Anti-Doping Agency lists thymosin beta-4 by name as a prohibited substance, placed in the peptides-and-growth-factors category that affects tissue repair and banned at all times rather than only in competition. In horse racing, integrity bodies have explicitly barred thymosin beta-4, and the substance sat at the center of high-profile racing doping cases that drew penalties for those involved.
Thymosin beta-4 is named on the WADA prohibited list and barred at all times, and its unscheduled, unapproved status under drug law does not lessen that prohibition, because anti-doping rules operate independently of drug-scheduling law.
Across countries the treatment varies in the details, but the record reports a common thread: mainstream regulators in developed markets have not approved TB-500 as a medicine for human use. Agencies comparable to the FDA generally treat unapproved injectable peptides as prescription-only or unapproved medicines, so an apparent ability to buy the compound online does not establish that it is lawful to import, possess, or use where the buyer lives.
Regulatory treatment of TB-500 is jurisdiction-specific, with comparable agencies in the EU, UK, Canada, and Australia generally treating unapproved injectable peptides as prescription-only or unapproved medicines, so the ability to buy it online does not establish that importing, possessing, or using it is lawful where the buyer lives.
Educational use only. This article describes what the published scientific and clinical literature reports about TB-500. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
